Welcome to our dedicated page for Ekso Bionics news (Ticker: EKSO), a resource for investors and traders seeking the latest updates and insights on Ekso Bionics stock.
Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) is a developer of exoskeleton and rehabilitation technologies for medical and industrial applications, and its news flow reflects this focus. Company press releases highlight product and technology developments, capital markets activity, strategic partnerships, and financial performance. Ekso Bionics regularly describes itself as an industry leader in exoskeleton technology that supports or enhances human strength, endurance, and mobility, with an emphasis on improving health and quality of life.
News updates for EKSO often cover clinical and rehabilitation initiatives, such as the launch of eksoUniversity, a virtual platform offering continuing education courses for physical therapists and physical therapy assistants who work with patients with neurological conditions. Other announcements detail agreements like Ekso Bionics’ role as the exclusive authorized U.S. sales agent and distributor for MediTouch’s BalanceTutor rehabilitation system, which uses a patented 4D perturbation treadmill and multiple sensors to help patients with impaired balance respond to unexpected disturbances while walking.
Investors and observers can also find coverage of Ekso Bionics’ technology roadmap, including its acceptance into the NVIDIA Connect program and related efforts to build a proprietary foundation model for human motion and integrate AI-enabled capabilities into its Enterprise Health and Personal Health exoskeleton devices. The company has reported proof-of-concept for an AI voice agent, Ekso Voice Agent, designed for intelligent control of its legacy EksoNR device.
In addition, EKSO news includes quarterly financial results, reverse stock split announcements, registered direct offerings of common stock, and secured loan agreements. Together, these updates provide insight into the company’s operating trends, capital structure decisions, and strategic priorities. This news page aggregates such disclosures so readers can follow developments in Ekso Bionics’ exoskeleton, rehabilitation, and AI initiatives over time.
Ekso Bionics (Nasdaq: EKSO) priced a private placement announced Jan 21, 2026 to sell 5,852 shares of Series B preferred stock and warrants to buy up to 355,960 common shares. The preferred has a stated value of $1,000 per share and converts into 711,922 common shares at a conversion price of $8.22. Warrants are exercisable at $8.22, expire five years after initial exercise, and initial exercise begins six months after closing. Gross proceeds are expected to be about $5.9 million; net proceeds will be used for working capital and general corporate purposes.
Ekso Bionics (Nasdaq: EKSO) announced an exclusive U.S. distribution agreement with MediTouch to act as the authorized sales agent and distributor for the BalanceTutor™ rehabilitation system in the United States, dated December 4, 2025.
The BalanceTutor uses a patented 4D perturbation treadmill with multiple force and movement sensors to simulate slips, trips, and stumbles while supporting patient weight via an overhead frame to promote safe reactive balance training in inpatient and outpatient rehabilitation settings.
Ekso said the product is complementary to its enterprise health exoskeleton offerings and will be marketed through its existing customer call points to increase awareness and adoption across U.S. physical rehabilitation facilities.
Ekso Bionics (Nasdaq: EKSO) announced a registered direct offering entered on October 28, 2025 to sell 769,490 shares of common stock at $4.81 per share in an at-the-market transaction under Nasdaq rules.
The offering is expected to close on or about October 30, 2025, with gross proceeds of approximately $3.7 million before placement agent fees and other offering expenses. Lake Street Capital Markets is the exclusive placement agent.
The company intends to use net proceeds for general corporate purposes, including research and development, selling, general and administrative costs, strategic initiatives and working capital. The shares are being offered under a Form S-3 shelf registration declared effective June 20, 2023.
Ekso Bionics (Nasdaq: EKSO) reported Q3 2025 results on Oct 28, 2025: revenue $4.2M (up 2% YoY, up 105% sequentially), gross margin 60.3% (up 680 bps YoY, driven by higher Enterprise Health sales and lower device cost), and net loss $1.4M (improved 31% YoY, $0.54 per share). Operating expenses declined across S&M, R&D and G&A mainly due to Employee Retention Credit benefits.
The company had $2.7M cash at Sept 30, 2025 and announced it is exploring strategic transactions, which may include divestiture or acquisition and could require substantial issuance of company securities.
Ekso Bionics (NASDAQ: EKSO), a leader in exoskeleton technology, reported its Q2 2025 financial results, showing significant challenges. Revenue declined to $2.1 million from $5.0 million in Q2 2024, primarily due to lower Enterprise Health device sales. The company posted a net loss of $2.7 million, or $1.24 per share.
Despite challenges, Personal Health products grew over 50% year-over-year in H1 2025. Notable developments include naming Bionic P&O as first Ekso Indego Personal device distributor, joining NVIDIA Connect program for AI development, launching an AI voice agent for EksoNR, and introducing eksoUniversity for physical therapy education.
Gross margin decreased to 40% from 53% year-over-year, while cash position stood at $5.2 million as of June 30, 2025.
Ekso Bionics (NASDAQ:EKSO), a leader in medical and industrial exoskeleton technology, has scheduled its Q2 2025 financial results release for July 28, 2025 after market close. The company will host a conference call at 1:30 PM PT / 4:30 PM ET to discuss financial performance and recent business developments.
Investors can join via phone by dialing 877-407-6184 (domestic) or 201-389-0877 (international). The presentation will also be available through a live webcast and archived on the company's investor relations website.
Ekso Bionics (Nasdaq: EKSO) has launched eksoUniversity, a new online continuing education platform for physical therapists (PTs) and physical therapy assistants (PTAs). The platform offers on-demand courses approved for CEUs in over 30 states, specifically targeting professionals working with neurological conditions.
CEO Scott Davis emphasized that while the platform is expected to generate incremental revenue, its primary value lies in educating the neurological physical therapy community about various treatment options. The courses help healthcare professionals maintain their licensing requirements while staying current with evolving treatment methods and technologies.
Ekso Bionics (NASDAQ: EKSO) has announced a revised effective date for its previously approved 1-for-15 reverse stock split, now scheduled for June 2, 2025, at 12:01 a.m. Pacific time. The company's outstanding shares will decrease from approximately 35.5 million to 2.4 million shares post-split. This action follows a Nasdaq non-compliance notice received in December 2024 regarding the minimum bid price requirement. The reverse split aims to raise the stock's trading price to meet Nasdaq's $1.00 minimum bid requirement for at least ten consecutive trading days. The split will affect all issued shares, including adjustments to stock options, warrants, and RSUs, with fractional shares being rounded up to the next whole share.
Ekso Bionics (NASDAQ: EKSO) has announced a 1-for-15 reverse stock split effective May 27, 2025. The split will reduce outstanding common stock from approximately 35,289,695 to 2,352,646 shares. The primary purpose is to raise the per-share trading price and regain compliance with Nasdaq's minimum bid price requirement of $1.00 for at least ten consecutive trading days.
The reverse split, approved by shareholders on May 16, 2025, will affect all issued shares, including adjustments to stock options, warrants, and restricted stock units. No fractional shares will be issued, with any fractional shares being rounded up. The company will maintain its "EKSO" trading symbol but will trade under a new CUSIP number 282644 400.
FAQ
What is the current stock price of Ekso Bionics (EKSO)?
What is the market cap of Ekso Bionics (EKSO)?
